MedPath

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Withdrawn
Conditions
Skin Cancers
Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Bladder Cancer
Bladder (Urothelial, Transitional Cell) Cancer
Registration Number
NCT01060319
Lead Sponsor
Stanford University
Brief Summary

We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease. The primary aim of this study is to develop strategies for prospective isolation/enrichment of CSCs from human tumors of different tissue origins. In addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for CSCs, in order to specifically target these CSCs as the endpoint of this study.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

N/A. We will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. This includes patients from all ages, gender and ethnicity background. Our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients).

Read More
Exclusion Criteria

N/A

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measurement of cancer stem cells (CSCs)The current study does not include the active involvement of patients. Our study involves the collection of tumor samples from patients after surgical procedures.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Stanford University School of Medicine

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath